Company profile: Allarity
1.1 - Company Overview
Company description
- Provider of biopharmaceutical oncology therapies and predictive diagnostics for personalized cancer treatment, utilizing DRP Technology to predict patient response and refine patient selection. Pipeline includes Dovitinib for renal cell carcinoma, Stenoparib, LiPlaCis, and 2X-111.
Products and services
- DRP® Technology: A diagnostic-grade platform that predicts individual cancer drug response using tumor biology and gene expression data, architected to refine patient selection and enhance clinical outcomes
- LiPlaCis®: A clinical-stage liposome formulation of cisplatin engineered for direct delivery to tumor sites, with completed Phase 2 trials in metastatic breast cancer
- 2X-111: A BBB-permeable liposomal doxorubicin architected for tumor delivery and capable of crossing the blood-brain barrier, with clinical activity against brain metastasis in breast cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allarity
Scorpion Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision oncology therapeutics, developing small-molecule inhibitors targeting the H1047X-mutant PI3Kα in solid tumors (STX-H1047-PI3Kα) and exon 20 insertion mutations in EGFR driving non-small cell lung cancer (STX-EGFR-EXON20).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scorpion Therapeutics company profile →
MTM Laboratories
HQ: Germany
Website
- Description: Provider of ISO 9001 and 13485 certified in-vitro diagnostics for early detection and diagnosis of cervical and other cancers; headquartered in Heidelberg, Germany, with subsidiaries in the United States, France, Italy and Spain; markets proprietary CINtec Histology Kit and CINtec.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MTM Laboratories company profile →
AnPac Bio
HQ: United States
Website
- Description: Provider of early cancer screening and detection services, offering the CDA Early Cancer Risk Assessment using Cancer Differentiation Analysis to evaluate early cancer risks, the APCS Pan-Cancer Screening to detect multiple cancer types, and the ADME Third Immune Defense Test to assess immune defense capabilities against diseases, including cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnPac Bio company profile →
X4 Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X4 Pharmaceuticals company profile →
JW Holdings
HQ: South Korea
Website
- Description: Provider of prescription drugs, over-the-counter drugs, and medical equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JW Holdings company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allarity
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allarity
2.2 - Growth funds investing in similar companies to Allarity
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allarity
4.2 - Public trading comparable groups for Allarity
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →